It is a clinical stage liquid biopsy company[2] and uses artificial intelligence algorithms for early detection of cancers and other diseases to improve survival rates.
The test algorithm makes use of the complete biological profile of the patient's serum sample rather than concentrating on a single biomarker for illness.
[8] Based on research conducted at Strathclyde University, Dxcover Limited has raised over £10 million for its technology that enables the early diagnosis of numerous malignancies.
[9] Existing investors lead by Eos Advisory LLP contributed £7.5 million in Series A funding, with further contributions from the University of Strathclyde, Mercia Fund Management, Scottish Enterprise, Social Investment Scotland Ventures, and Norcliffe Capital.
As Dxcover continues to expand its U.S. network, Boston-based life science investor Mark Bamforth of Thairm Bio also joined the round.